David is a Partner at Soleus Capital where he focuses on private and public therapeutic and next-generation diagnostic companies. David has served on the board or as an observer for a number of companies including Antios Therapeutics and Parse Biosciences. Prior to joining Soleus in 2018, David completed his PhD at MIT in Immunology and Oncology after finishing his undergraduate studies at Princeton University.